Monte Rosa books $87.5m Novartis payments and readies three mid-stage studies for MRT-8102

Monte Rosa Therapeutics received $87.5 million in milestone payments from Novartis after the Swiss drugmaker began two mid-stage studies of MRT-6160, the companies' partnered programme. The trials, both Phase 2a/b, are in Sjögren's disease and psoriatic arthritis. The company disclosed the payments with its third-quarter results on 5 November.

The Massachusetts-based biotech ended the quarter with $582.6 million in cash, which it says should finance operations into 2029. The facts provided do not break down how much of that balance reflects the Novartis payments, nor do they give quarterly revenue or spending figures.

On its wholly owned asset, Monte Rosa intends to take MRT-8102, a degrader of the protein NEK7, into three Phase 2 studies. A gout trial is due to start in the fourth quarter of 2026, with studies in coronary artery disease and hidradenitis suppurativa pencilled in for the first half of 2027.

The plan follows the Phase 1 GFORCE-1 study, which enrolled 108 obese people at elevated cardiovascular risk. The company reports that MRT-8102 reduced NEK7 levels by roughly 80% to 90%, and that adverse events occurred at rates comparable to placebo. These are company-reported findings; the facts available do not include detailed data tables or efficacy results.

Moving into three indications will enlarge the safety database considerably, and the placebo-like tolerability seen in Phase 1 will now face testing in bigger and more varied patient groups.